CA2360311A1 - Improved dialysis solutions and methods - Google Patents

Improved dialysis solutions and methods Download PDF

Info

Publication number
CA2360311A1
CA2360311A1 CA002360311A CA2360311A CA2360311A1 CA 2360311 A1 CA2360311 A1 CA 2360311A1 CA 002360311 A CA002360311 A CA 002360311A CA 2360311 A CA2360311 A CA 2360311A CA 2360311 A1 CA2360311 A1 CA 2360311A1
Authority
CA
Canada
Prior art keywords
methods
dialysis solutions
improved dialysis
dialysis
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002360311A
Other languages
French (fr)
Other versions
CA2360311C (en
Inventor
Raja Khalifah
Billy Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
Raja Khalifah
Billy Hudson
Kansas University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raja Khalifah, Billy Hudson, Kansas University Medical Center filed Critical Raja Khalifah
Publication of CA2360311A1 publication Critical patent/CA2360311A1/en
Application granted granted Critical
Publication of CA2360311C publication Critical patent/CA2360311C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides improved dialysis compositions and methods for dialysis comprising utilizing the disclosed AGE inhibitors, together with methods to reduce dialysis-related complications and disorders.
CA002360311A 1999-04-06 2000-04-06 Improved dialysis solutions and methods Expired - Fee Related CA2360311C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12790699P 1999-04-06 1999-04-06
US60/127,906 1999-04-06
PCT/US2000/009241 WO2000059493A2 (en) 1999-04-06 2000-04-06 Improved dialysis solutions and methods

Publications (2)

Publication Number Publication Date
CA2360311A1 true CA2360311A1 (en) 2000-10-12
CA2360311C CA2360311C (en) 2003-03-18

Family

ID=22432569

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360311A Expired - Fee Related CA2360311C (en) 1999-04-06 2000-04-06 Improved dialysis solutions and methods

Country Status (4)

Country Link
EP (1) EP1165079A2 (en)
AU (1) AU4078300A (en)
CA (1) CA2360311C (en)
WO (1) WO2000059493A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002237667A1 (en) 2000-11-20 2002-05-27 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049940C (en) * 1990-02-19 1996-03-05 Jun Inoue Maillard's reaction inhibitor compositions
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
WO1999007419A1 (en) * 1997-08-07 1999-02-18 Ajay Gupta Dialysis solutions containing water soluble vitamins and nutrients
EP1108434B1 (en) * 1998-08-24 2014-05-14 Kurokawa, Kiyoshi Drugs for relieving carbonyl stress and peritoneal dialysates

Also Published As

Publication number Publication date
EP1165079A2 (en) 2002-01-02
WO2000059493A3 (en) 2001-02-01
CA2360311C (en) 2003-03-18
AU4078300A (en) 2000-10-23
WO2000059493A2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
AU6198700A (en) Process for producing phenyl-alkanes compositions produced therefrom, and uses thereof
AP2002002529A0 (en) 2,4-Diaminopyrimidine compounds useful as immunosupressants
AU2001291173A1 (en) Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
HK1059254A1 (en) Acylacetonitrile compound, process for preparationthereof, and miticide containing the same.
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
WO2002102586A3 (en) Cellulose-polymer composites and methods for manufacturing same
AU2001289729A1 (en) Perfluoroalkyl-containing complexes comprising sugar residues, method for producing the same and use thereof
CA2369825A1 (en) Microstructured components
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
WO2000053841A3 (en) Unsupported flat linoleum structure and method of producing same
AU4122901A (en) Novel 7,8-dihydro-xanthenone-8-carboxylic acid derivative and novel microbe producing the same
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
AU2003241785A1 (en) Intravenous composition, process for producing the same and preparation thereof
CA2360311A1 (en) Improved dialysis solutions and methods
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
WO2001042250A3 (en) Process for production of diphenyl-dialkoxysilane, phenylalkyl-dialkoxysilane, octaphenylcyclotetrasiloxane and sym-tetraalkyltetraphenyl-cyclotetrasiloxane
WO2001046128A3 (en) Tryptase inhibitors
USD444182S1 (en) Set of heximoes
AU2001242750A1 (en) Novel protein, process for producing the same and use thereof
AU7773700A (en) Method for the production or preparation of 2,6-dichlorotoluol
WO2003020767A3 (en) Antibodies against caspase-8, their preparation and use
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
HK1049485A1 (en) DithiepinoÄ6,5-BÜpyridines, and related compositions, methods of producing and uses.
AU2001267587A1 (en) Method for the production of n,n'-carbonyldiazoles and azolide salts
AU2401401A (en) Migrastatin, process for producing the same and medicinal compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190408